Characterization of cannabinoids, endocannabinoids, and biomarkers in adolescentsProtocol #: 20-0553 Location: University of Colorado Hospital |
Multiomics Investigation of Marijuana UseThis research study seeks to learn more about biomarkers and biological pathways associated with marijuana use. We are enrolling adults who are marijuana users or non-users. The study involves filling out online surveys and one on-campus visit to give a blood, urine, and hair sample. If you want to learn more about the study please contact Kristen Raymond at kristen.raymond@cuanschutz.edu. The specific aims of the project are to: 1) Discover biomarkers associated with marijuana use. 2) Discover biological pathways associated with marijuana use. 3) Exploratory Aim: Test whether peripheral endocannabinoid levels vary with marijuana use and predict marijuana craving. Protocol #: 18-0853 Location: University of Colorado Hospital |
Effects of Cannabis Use in Cancer Patients: A Feasibility StudyProtocol #: 18-0836 Locations: University of Colorado Hospital; University of Colorado, Boulder |
Inhaled Cannabis, Oxidative Stress and the Pulmonary Innate Immune ResponseThis study evaluates the effect of long term cannabis/marijuana smoking on lung health. This study evaluates the effect of long term cannabis/marijuana smoking on lung health. Protocol #: 14-1957 Location: University of Colorado Hospital |
A double-blind, placebo-controlled crossover study comparing the analgesic efficacy of cannabis versus oxycodonePRIMARY AIMS: (1) To compare the effects of cannabis versus oxycodone versus placebo on spontaneous chronic spine pain relief, as measured by change in score on the 10-point Numeric Rating Scale (NRS); (2) To compare the effects of cannabis versus oxycodone versus placebo on experimental pain analgesia, as measured by change in Experimental Pain Threshold (EPTh), in both patients with chronic spine pain and healthy controls. SECONDARY AIMS: (1) To compare the effects of cannabis versus oxycodone versus placebo on chronic spine pain, as measured by the Patient Global Impression of Change (PGIC) scale; (2) To compare the effects of cannabis versus oxycodone versus placebo on subjective reports of drug effects, psychoactive effects, and mood; (3) To compare the effects of cannabis versus oxycodone versus placebo on tests of neurocognitive functioning (Wechsler Adult Intelligence Scale (WAIS-III) Digit Symbol Test, the Hopkins Verbal Learning Test Revised (HVLT), and the Grooved Pegboard Test); (4) To compare the effects of cannabis versus oxycodone versus placebo on Standardized Field Sobriety Tests (SFST). Protocol #: 14-1909 Locations: CTRC-adult; University of Colorado Hospital |